ReviewClinical pharmacology and therapeutics2022
Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
Review in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Defining a standards framework for ophthalmology real-world data methodologies through an expert-led Delphi consensus.Eye (London, England) · 2026Article
- Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.Current treatment options in oncology · 2026Review
- Epidemiology, treatment patterns, and survival outcomes of patients with mantle cell lymphoma in Germany: a retrospective analysis of administrative claims data.Annals of hematology · 2026Observational
- Endometriosis treatment pathways in the largest private health insurance in Brazil: A real-world data study.PloS one · 2026Article
- Multiscale Design of Dental Restorative Materials: Mechanistic Foundations, Technological Innovations, and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Article
- Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data.Annals of hematology · 2025Observational
- Transforming Care in China by Using Public-Private Partnerships to Unlock the Power of Patient-Centered Real-World Data.Pharmaceutical medicine · 2025Review
- Strengthening vaccine effectiveness research to rebuild public trust: A call for global participation.PLOS global public health · 2025Article
- Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Real-world evidence: experiences and challenges for decision making in Latin America.International journal of technology assessment in health care · 2023Article
- Data Challenges for Externally Controlled Trials: Viewpoint.Journal of medical Internet research · 2023Article
- Contemporary Databases in Real-world Studies Regarding the Diverse Health Care Systems of India, Thailand, and Taiwan: Protocol for a Scoping Review.JMIR research protocols · 2022Article
- Global Health Strategies in the Face of the COVID-19 Pandemic and Other Unprecedented Threats.Journal of Korean medical science · 2022Review
- Transferability of real-world data across borders for regulatory and health technology assessment decision-making.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For low- and middle-income countries (LMICs) to benefit from real-world evidence (RWE)/real-world data (RWD) in both product registration ("regulatory") decision making and in product utilization policy ("policy") decision making, they need to overcome several challenges. They need to deploy more electronic health records systems (EHRs), adjust for confounder variables, build trust between stakeholders, and create laws and regulations for local generation of data that are assented for secondary use. The role of procurers and their use of RWE/RWD in the LMIC context likewise is in a state of ongoing development. Procurers of health products are strong players currently in the "access" chain as LMICs continue to work on strengthening governmental health technology assessment (HTA) bodies. Procurers' use of RWE is presently at an early stage and is mostly indirect, leveraging RWE results that are produced by researchers in high-income countries (HICs), often under considerably different regulatory and policy objectives and constraints compared to LMICs' epidemiology and priorities. Pending wider deployment of EHRs and other RWE sources, stakeholders must realize that populations from HIC RWE (i) can be devised to closely resemble phenotypic patterns in LMIC populations and (ii) can be analyzed to align with LMICs' unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.